Who makes Cohort 1 - FP-045 oral solution?

Cohort 1 - FP-045 oral solution is developed by Foresee Pharmaceuticals Co., Ltd..

What development phase is Cohort 1 - FP-045 oral solution in?

Cohort 1 - FP-045 oral solution is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Cohort 1 - FP-045 oral solution

Foresee Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	Cohort 1 - FP-045 oral solution
Sponsor	Foresee Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cohort 1 - FP-045 oral solution CI brief — competitive landscape report
Cohort 1 - FP-045 oral solution updates RSS · CI watch RSS
Foresee Pharmaceuticals Co., Ltd. portfolio CI